Known for his skills in business strategy, private equity, venture capital and seed capital, Alexis Bailo de Spoelberch recognizes a promising venture when he sees it. One of his latest endeavors in the pipeline is at-home testing for diseases. It’s not all about business though, as Alexis hopes for the venture to be able to deliver a win-win solution for many nations battling deadly and infectious but preventable and treatable diseases. Because science and technology have not been able to catch up with the treatment and cure of common ailments such as cancer and infectious diseases, the at-home disease testing concept may prove to be the effective connection between detection and prevention. This healthcare innovation operates on the simple concept of prevention being worth a pound of cure. In this case, early detection could lead to the prevention of untimely deaths. This is especially important because many ailments are frequently detected only at the terminal stages.
Inspired by the huge potential in growth of the medical technology and diagnostics market, Alexis Bailo de Spoelberch and his brother, Patrice Bailo de Spoelberch saw an opportunity to potentially invest in a mutual fund wholly dedicated to the medical industry. Long before, they had already been known as savvy and competent businessmen from Belgium, with investments spread across many different industries. Their recent activity in the field of medical technologies shows how keenly aware they are of innovative ventures that promise a hefty return of investment. Aside from at-home testing kits for a myriad of illnesses, their potential investments include next-gen aortic valves, new weight loss treatments, insulin patches and many more.
With those potential investments, Alexis Bailo de Spoelberch and his brother are sure to give a strong signal for other big individual players like them to also test the waters in this industry as well. This means consumers will have more choices in a larger market, resulting in different companies investing in better equipment, more advanced technology and an increasing number of diseases to be tested for. This will be good for the industry as a whole.